FORM 4

1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no
longer subject to Section
16. Form 4 or Form 5
obligations may
continue. See Instruction

Filed

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APF	PROVAL
OMB Number:	3235-0287
Expires:	December 31, 2014
Estimated a	verage burden
hours per response	0.5

1. Name and A		eporting Person*	2. Issuer Name and Ticker or Trading Symbol Pacira Pharmaceuticals, Inc. [PCRX]	5. Relationship of Reporting Person(s) to Issuer
(Last) 400 SOUTH E 1200	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/15/2013	(Check all applicable) X Director 10% Owner Officer (give title below) (specify below)
(Street) SAN MATEO (City)	CA (State)	94402 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

	Table I -	Non-Derivative Se	curities	Acc	quired, D	ispo	sed of, or	Beneficially Ov	vned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Instr. 8)		(A) or Dis	(A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership
			Code	V	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)	or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock	03/15/2013		J (11)		200,000	D	\$ 0	0	D (12) (9) (10)	
Common Stock	03/15/2013		J ⁽¹¹⁾		25,133	Α	\$ 0	67,966	D (13) (9) (10)	
Common Stock	03/18/2013		S ⁽¹⁾		28,956	D	\$ 29.2 (2)	530,497	D (3) (9) (10)	
Common Stock	03/18/2013		S ⁽¹⁾		23,969	D	\$ 29.2 (2)	24,688	D (4) (9) (10)	
Common Stock	03/18/2013		S ⁽¹⁾		28,558	D	\$ 29.2 (2)	29,415	D (5) (9) (10)	
Common Stock	03/18/2013		S ⁽¹⁾		29,825	D	\$ 28.19 (6)	500,672	D (3) (9) (10)	
Common Stock	03/18/2013		S ⁽¹⁾		24,688	D	\$ 28.19 (6)	0	D (4) (9) (10)	
Common Stock	03/18/2013		S ⁽¹⁾		29,415	D	\$ 28.19 (6)	0	D (5) (9) (10)	
Common Stock	03/19/2013		S ⁽¹⁾		38,250	D	\$ 27.66 (7)	462,422	D (3) (9) (10)	
Common Stock	03/19/2013		S ⁽¹⁾		46,339	D	\$ 26.95 (8)	416,083	D ⁽³⁾ ⁽⁹⁾ ⁽¹⁰⁾	

			Derivative S (e.g., puts, c											Owned		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transad Code (Instr. 8	ction	5. Numl	per of rative rities ired	6. Date Exerci Expira	e isabl	e and	7. T Amo Uno Sec	itle and bunt of derlying urities tr. 3 and	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares				
		dress of Repo	_	*												
(Last) 400 SC	OUTH EL ((First) CAMINO REA		(Middle	∋)											
(Street)	•	CA		94402				_								
(City)		(State)		(Zip)				_								
Sander (Last)	ling VI Be	dress of Repo teiligungs Gml (First)	bH & Co KG	(Middle	e)			_								
(Street))	CAMINO REA		94402				_								
(City)		(State)		(Zip)				-								
1. Name		dress of Repo	orting Persor													
(Last) 400 SC	OUTH EL	(First) CAMINO REA		(Middle	e)											
(Street)	•	CA		94402				-								
(City)		(State)		(Zip)												
		dress of Repo	_	*												
(Last)		(First)		(Middle	e)			-								

94402

11. Nature of Indirect Beneficial Ownership (Instr. 4)

(City) (State) (Zip)

1. Name and Address of Reporting Person*

400 SOUTH EL CAMINO REAL, SUITE 1200

CA

(Street)
SAN MATEO

Sanderling Ventui	re Partners VI Co Ir	vestment Fund LP	
(Last)	(First)	(Middle)	
400 SOUTH EL C	CAMINO REAL, SU	ITE 1200	
(Street)			
SAN MATEO	CA	94402	
(City)	(State)	(Zip)	
1. Name and Add	Iress of Reporting	Person*	
MIDDLE TON FK	LDA		
(Last)	(First)	(Middle)	
(Last)		,	
(Last)	(First)	,	
(Last) 400 SOUTH EL C	(First)	,	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on February 4, 2013
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$28.59 to \$29.58, inclusive. The reporting person undertakes to provide to Pacira Pharmaceuticals, Inc., any security holder of Pacira Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) of this Form 4.
- 3. The securities are held directly by Sanderling Venture Partners VI, L.P.
- 4. The securities are held directly by Sanderling VI Beteiligungs GmbH & Co. KG. The address for Sanderling VI Beteiligungs GmbH & Co. KG is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.
- 5. The securities are held directly by Sanderling VI Limited Partnership. The address for Sanderling VI Limited Partnership is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.
- 6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$27.70 to 28.58, inclusive. The reporting person undertakes to provide to Pacira Pharmaceuticals, Inc., any security holder of Pacira Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) of this Form 4.
- 7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$27.21 to \$28.20, inclusive. The reporting person undertakes to provide to Pacira Pharmaceuticals, Inc., any security holder of Pacira Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) of this Form 4.
- 8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$26.52 to \$27.20, inclusive. The reporting person undertakes to provide to Pacira Pharmaceuticals, Inc., any security holder of Pacira Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) of this Form 4.
- 9. Fred Middleton, a member of the Board of Directors of the Issuer, is a managing director of Middleton, McNeil, Mills & Associates VI, LLC, which has the ultimate voting and investment power over shares held of record by Sanderling Venture Partners VI, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling VI Limited Partnership and Sanderling Venture Partners VI Co-Investment Fund, L.P. and he may be deemed to have voting and investment power over shares held of record by Sanderling Venture Partners VI, L.P.,
- 10. Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling VI Limited Partnership and Sanderling Venture Partners VI Co-Investment Fund, L.P. Mr. Middleton is the owner of Sanderling Ventures Management VI and he may be deemed to have voting and investment power over shares held of record by Sanderling Ventures Management VI. Mr. Middleton disclaims beneficial ownership over the shares held by Sanderling Ventures and its affiliates, except to the extent of his pecuniary interest therein.
- 11. On March 15, 2013, Sanderling Venture Partners VI Co-Investment Fund, L.P. distributed an aggregate of 1,000,000 shares of the Issuer's common stock pro rata to its partners, including Sanderling Ventures Management VI, for no consideration (the "Distribution"). Sanderling Ventures Management VI subsequently distributed the securities received in the Distribution to its underlying members (the "GP Distribution").
- 12. The securities were held directly by Sanderling Ventures Management VI. The address for Sanderling Ventures Management VI is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.
- 13. The securities are held directly by Mr. Middleton. On March 15, 2013, Mr. Middleton received 25,133 shares of the Issuer's common stock as a result of the GP Distribution. The address for Mr. Middleton is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200,

/s/ See Exhibit 99.1

03/20/2013

** Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4(b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

SANDERLING VENTURE PARTNERS VI, L.P.

By: Middleton, McNeil, Mills & Associates VI, LLC

By: /s/ Fred A. Middleton

Fred A. Middleton Managing Director

SANDERLING VI BETEILIGUNGS GMBH & CO. KG

By: Middleton, McNeil, Mills & Associates VI, LLC

By: /s/ Fred A. Middleton

Fred A. Middleton Managing Director

SANDERLING VENTURES MANAGEMENT VI

By: /s/ Fred A. Middleton

Fred A. Middleton

Owner

SANDERLING VI LIMITED PARTNERSHIP

By: Middleton, McNeil, Mills & Associates VI, LLC

By: /s/ Fred A. Middleton

Fred A. Middleton Managing Director

SANDERLING VENTURE PARTNERS VI CO-INVESTMENT FUND, L.P.

By: Middleton, McNeil, Mills & Associates VI, LLC

By: /s/ Fred A. Middleton

Fred A. Middleton Managing Director

/s/ Fred A. Middleton

Fred A. Middleton